NCT03027934撤回4 期
A Single Center, Randomized, Open Label, Crossover Study With Ticagrelor and Prasugrel to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 主要终点
- Aggregation Response
研究概览
简要总结
The overall objective of this study is to assess P2Y12 inhibition ex vivo in blood samples obtained from diabetic subjects who will be administered one of the two P2Y12 antagonists in a cross-over design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of informed consent prior to any study specific procedures
- •Male or female aged 18 to 70 years, inclusive.
- •Documented current medical history of diabetes controlled by either medication or diet and/or exercise.
- •Women must have a negative urine pregnancy test.
排除标准
- •Pregnant or lactating females, or females of child-bearing potential (i.e., those who are not chemically or surgically sterilized or who are not post-menopause) or those who are not willing to use a medically accepted method of contraception that is considered reliable in the judgement of the investigator throughout the duration of the study or females who have a positive pregnancy test at screening.
- •Weight of less than 135 lbs.
- •Currently prescribed and taking clopidogrel (generic or Plavix), ticagrelor (Brilinta) or prasugrel (Effient) or have taken within the past 10 days.
- •Current medications:
- •PAR-1 antagonist (vorapaxar/Zontivity) or within the last month.
- •Phosphodiesterase inhibitors such as cilostazol (Pletal).
- •Glycoprotein IIb/IIIa inhibitors or within the last ten days (Integrilin, Aggrastat, ReoPro).
- •Adenosine reuptake inhibitors such as dipyridamole (Aggrenox, Persantine)
- •Heparin including low molecular weight heparin.
- •Factor Xa inhibitors (e.g., enoxaparin, rivaroxaban, apixaban, and edoxaban).
- •Direct thrombin inhibitors (e.g., hirudin, bivalirudin, dabigatran.
- •Concomitant therapy with strong CYP3A inhibitors, such as atanazavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazadone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconizole,
- •Concomitant therapy with potent CYP3A inducers, such as rifampin, phenytoin, carbamazepine, and phenobarbital.
- •Increased bleeding risk including:
- •Recent (within 30 days) GI bleeding
- •Active pathological bleeding
- •Any history of intracranial, intraocular, retroperitoneal, or spinal bleeding
- •Prior history of transient ischemic attack or stroke
- •Recent (within 3 months) major trauma
- •Sustained uncontrolled hypertension (systolic blood pressure [SBP] > 180mmHg or diastolic blood pressure [DBP] > 100mmHg
- •History of hemorrhagic disorders that can increase the risk of bleeding (e.g., hemophilia, von Willebrand's disease)
- •Patients that have used within 30 days of screening, any oral or parenteral anti-thrombotic agent.
- •Platelet count less than 100,000 mm3 or hemoglobin < 10g/dL
- •Contraindication or other reason that ticagrelor or prasugrel should not be administered (e.g., known hypersensitivity to medication or any medication component)
- •A history of alcohol and/or substance abuse that could interfere with conduct of the trial.
- •Known active or recurrent hepatic disorder (including cirrhosis, hepatitis B and hepatitis C, or confirmed (ALT/AST) levels > 3 times ULN or total bilirubin > 2 times ULN at screening.
- •Scheduled for revascularization (e.g., PCI, CABG) during the study period.
- •Any Acute Coronary Syndrome (ACS) event within the past 6 months.
- •Participation in another investigational drug or device study within 30 days of dosing.
- •Any acute or chronic unstable condition in the past 30 days or other condition which, in the opinion of the investigator, may either put the subject at risk or influence the result of the study (e.g., active cancer, risk for non-compliance, risk for lost to follow-up).
研究组 & 干预措施
Group 1
Active Comparator
干预措施: Ticagrelor (Drug)
Group 2
Active Comparator
干预措施: Ticagrelor (Drug)
Group 1
Active Comparator
干预措施: Prasugrel (Drug)
Group 2
Active Comparator
干预措施: Prasugrel (Drug)
结局指标
主要结局
Aggregation Response
时间窗: 23 hr Day 5
Comparison of aggregation response using ADP in subjects receiving prasurgrel versus ticagrelor
次要结局
- Reticulated Platelet Reactivity Index (PRI)(23 hr Day 5)
研究者
相似试验
撤回
2 期
The Multicenter Topic TrialChronic Obstructive Pulmonary DiseaseNCT04066751University of Alabama at Birmingham
已完成
1 期
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or LymphomasMetastatic CancerSolid TumorLymphomaNCT03489369Symphogen A/S15
已完成
2 期
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's TypeAlzheimer DiseaseNCT00153010Boehringer Ingelheim430
终止
1 期
BAY1238097, First in ManNeoplasmsNCT02369029Bayer8
已完成
2 期
A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular DysfunctionHeart FailureNCT02452515Bayer49